Year-over-year earnings per share growth for the last twelve months: NextCure, Inc. (NXTC)
Stable management with a global reputation provides NextCure, Inc. (NXTC) with a high level of credibility. The quarterly shift in earnings per share confirms the effectiveness of cost management, while 59.60 represents the latest level value. Growth is based on the robotization of tissue analysis and successes in clinical trials of antibodies against solid tumors, paving the way for partnerships with pharma behemoths.
Comprehensive metric breakdowns and analytics for NextCure Corporation (NXTC)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- book capitalization data:
- debt and liquidity details:
- earnings and market multiples details:
NXTC - Final Profit|Projected Future Earnings NextCure, Inc.|NXTC - Market Cap to Earnings|Future Price to Earnings NextCure Corp|NXTC - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple NextCure Corp|NXTC - Operating profit EBITDA|Earnings per share for the last twelve months NextCure|NXTC - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months nextcure.com|NXTC - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year NextCure, Inc.
Comprehensive company analysis:NextCure, NXTC
For NextCure, Inc. (NXTC), which holds exclusive patents for the FIND platform, quarterly EPS variability reflects net income per share dynamics while filtering out market distortions under strict FDA oversight. This indicator measures the percentage change in earnings over three months, allowing investors to distinguish actual cash flow from paper reports and assess the risk of overpayment during an uptrend.
Competitors of NextCure, Inc.
IBRX: Quarterly EPS earnings growth|IMCR - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Janux Pharma|Year-over-year net earnings per share growth for the last 12 months Arcus Corp (RCUS)|Year-over-year earnings per share growth for the last twelve months Zymeworks Inc. (ZYME)|Year-over-year net earnings per share growth for the last 12 months tangotx.com TNGX|Iovance Biotherapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Immatics NV IMTX|XNCR - Year-over-year earnings per share growth for the last twelve months|CMPX (Compass Therapeutics Corp) - Year-over-year earnings per share growth for the last 12 months|Replimune Group, Inc. (REPL) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months lyell.com (LYEL)|Year-over-year net earnings per share growth for the last 12 months IPHA|PYXS - Net earnings per share growth for the trailing year|Year-over-year net earnings per share growth for the last 12 months CGEN (Compugen Ltd.)|Year-over-year earnings per share growth rate for the last twelve months IOBT|Quarterly EPS earnings growth STRO (Sutro Biopharma, Inc.)|Year-over-year earnings per one share growth for the last 12 months INKT|Werewolf - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Immix Biopharma, Inc.|ALX Oncology (ALXO) - Year-over-year earnings per share growth for the last twelve months|Cue Biopharma Inc. - Year-over-year earnings per one share growth for the last 12 months|PDSB (PDS Biotech) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Sonnet BioTherapeutics Holdings Inc.|Year-over-year earnings per share growth for the last twelve months MAIA Biotechnology, Inc. (MAIA)|LIMN: Year-over-year net earnings per share trend for the last twelve months|LAVA Therapeutics - Year-over-year net earnings per share growth for the last 12 months|Leap Therapeutics Inc (LPTX) - Earnings per share growth in annualized terms for the last twelve months|INTS - Year-over-year earnings per share growth for the last twelve months|SNSE (Sensei Biotherapeutics) - Year-over-year earnings per share growth for the last 12 months|TOVX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Gritstone bio (GRTS)|Year-over-year net earnings per share growth for the last 12 months KA|Year-over-year earnings per share growth for the last 12 months NEXI (NexImmune Corporation)|Year-over-year net earnings per share growth for the last 12 months TSBX (Turnstone Biologics)|Year-over-year earnings per share growth rate for the last twelve months VCNX|Quarterly EPS earnings growth HARP (Harpoon Therapeutics, Inc.)
